• 1
    Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signalling network: receptor heterodimerisation in development and cancer. EMBO J 2000; 19: 315967.
  • 2
    Barros FFT, Powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerisation and treatments. Histopathology 2010; 56: 56072.
  • 3
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 17781.
  • 4
    Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer. J Clin Oncol 2009; 27: 583847.
  • 5
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 165972.
  • 6
    Smith I, Procter M, Gelber RD, et al. 2-Year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised control trial. Lancet 2007; 369: 2936.
  • 7
    Cho H-S, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 75660.
  • 8
    Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum HER2/neu predicts response and progression free survival to trastuzumab-based treatments in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 161824.
  • 9
    Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung M-C, et al. PTEN activation contributes to tumour inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 11727.
  • 10
    Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395402.
  • 11
    Yonemori K, Tsuta K, Shimizu Y, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2009; 26: 3449.
  • 12
    Wendt A, Thompson VF, Goll DE. Interaction of calpastatin with calpain: a review. Biol Chem 2004; 385: 46572.
  • 13
    Huang Y, Wang KK. The calpain family and human disease. Trends Mol Med 2001; 7: 35562.
  • 14
    Glading A, Überall F, Keyse SM, Lauffenburger DA, Wells A. Membrane proximal ERK signalling is required for m-calpain activation downstream of epidermal growth factor receptor signalling. J Biol Chem 2001; 276: 233418.
  • 15
    Xu L, Deng X. Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of μ- and m-calpains. J Biol Chem 2006; 281: 3556775.
  • 16
    Cortesio CL, Chan KT, Perrin BJ, Burton N, Zhang S, Zhang Z-Y, Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadiopodia dynamics and breast cancer cell invasion. J Cell Biol 2008; 180: 95771.
  • 17
    Glading A, Chang P, Lauffenburger DA, Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signalling pathway. J Biol Chem 2000; 275: 23906.
  • 18
    Glading A, Bodnar RJ, Reynolds IJ, Shiraha H, Satish L, Potter DA, Blair HC, Wells A. Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal related kinase mediated phosphorylation. Mol Cell Biol 2004; 24: 2499512.
  • 19
    Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. HER2/neu overexpression induces NFκB via a PI3-kinase-Akt pathway involving calpain mediated degredation of IκB-α that can be inhibited by the tumour suppressor PTEN. Oncogene 2001; 20: 128799.
  • 20
    Kulkarni S, Reddy KB, Esteva FJ, Moore HCF, Budd GT, Tubbs RR. Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 2010; 29: 133950.
  • 21
    Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG. Integrin α2-mediated ERK and calpain activation play a role in cell adhesion and motility via focal adhesion kinase signalling. J Biol Chem 2006; 281: 8497510.
  • 22
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumour marker prognostic studies (REMARK). Nat Clin Pract Oncol 2005; 2: 41622.
  • 23
    Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 34050.
  • 24
    Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: a new bioinformatics tool for biomarker assessment and outcome based cut point optimisation. Clin Cancer Res 2004; 10: 72529.
  • 25
    Tan M, Li P, Klos KS, Lu J, Lan K-H, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 2005; 65: 185867.
  • 26
    Liu L, Xing D, Chen WR, Chen T, Pei Y, Gao X. Calpain mediated pathway dominates cisplatin induced apoptosis in human lung adenocarcinoma cells as determined by real time single cell analysis. Int J Cancer 2008; 122: 221022.
  • 27
    Hill JW, Hu JJ, Evans MK. OGG1 is degraded by calpain following oxidative stress and cisplatin exposure. DNA Repair 2008; 7: 64854.
  • 28
    Chen H, Libertini SJ, Wang Y, Kung H-J, Ghosh P, Mudryj M. ERK regulates calpain-2 induced androgen receptor in CWR22 relapsed prostate tumour cell lines. J Biol Chem 2010; 285: 236874.
  • 29
    Mohammed RAA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO. Improved methods for detecting lymphovascular invasion demonstrate it that is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007; 31: 182533.
  • 30
    Neumar RW, Meng FH, Mills AM, Xu YA, Zhang C, Welsh FA, Siman R. Calpain activity in rat brain after transient forebrain ischemia. Exp Neurol 2001; 170: 2735.
  • 31
    Gonçalves I, Nitulescu M, Saido TC, Dias N, Pedro LM, Fernandes e Fernandes J, Ares MPS, Pörn-Ares I. Activation of calpain-1 in human carotid artery atherosclerotic lesions. BMC Cardiovasc Disord 2009; 9: 26.
  • 32
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 167384.